BioWorld

June 5, 2009

View Archived Issues

Still No Winner in Acute HAE; FDA Wants New Cinryze Trial

Another runner has stumbled on a regulatory hurdle on the race to get the first acute hereditary angioedema (HAE) drug to market. (BioWorld Today) Read More

With No Partner, Anadys Cuts Jobs and Raises $17M

Read More

New Study Describes Immune Mechanisms of Anaphylaxis

Read More

Experts: Health Reform Must Address Diabetes

Read More

Adolor Cuts Staff 28% to Focus on Entereg

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More